Macular Ganglion Cell Analysis (GCA) of the Cirrus HD-OCT in Glaucoma



Status:Completed
Conditions:Ocular, Orthopedic
Therapuetic Areas:Ophthalmology, Orthopedics / Podiatry
Healthy:No
Age Range:40 - Any
Updated:5/27/2013
Start Date:November 2010
End Date:March 2011

Use our guide to learn which trials are right for you!


To determine the area under the Receiver Operator Characteristic Curve (AUC) for the
Ganglion Cell Analysis (GCA) average thickness.


To determine the area under the Receiver Operator Characteristic Curve (AUC) for the
following GCA parameters:

1. Minimum thickness

2. Supero-temporal thickness

3. Superior thickness

4. Supero-nasal thickness

5. Infero-temporal thickness

6. Inferior thickness

7. Infero-nasal thickness

Inclusion Criteria:

- Age of 40 years or older

- Diagnosed to have glaucoma by the Principal Investigator or co-investigator

- Able and willing to make the required study visits

- Able and willing to give consent and follow study instructions

Exclusion Criteria:

Ophthalmic:

- Best corrected visual acuity in either eye worse than 20/40 on a Snellen chart or on
a Snellen equivalent acuity chart.

- Refractive error outside -12.00D to +8.00D spherical range or >-3.00D cylinder.

- Previous vitreoretinal surgery in study eye.

- Vitreoretinal traction or epiretinal membrane in the study eye.

- Any active infection of anterior or posterior segments.

- Evidence of diabetic retinopathy, diabetic macular edema, or other vitreoretinal
disease in the study eye upon dilated examination, or upon evaluation of retinal
photos.

Systemic:

- History of diabetes, leukemia, AIDS, uncontrolled systemic hypertension, dementia or
multiple sclerosis.

- A life threatening or debilitating disease.

- Participation in any study involving a non-FDA approved investigational drug (IND)
within the past month, or ongoing participation in a study with a non-FDA approved or
cleared investigational device (IDE).

- Current or recent (within the past 14 days) use of an agent with photosensitizing
properties by any route (e.g., Visudyne®, ciprofloxacin, Bactrim®, doxycycline,
etc.).

- Concomitant use of hydrochloroquine and/or chloroquine.
We found this trial at
4
sites
Salt Lake City, Utah 84107
?
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
900 Northwest 17th Street
Miami, Florida 33136
?
mi
from
Miami, FL
Click here to add this to my saved trials
Dallas, Texas 75231
?
mi
from
Dallas, TX
Click here to add this to my saved trials
Palo Alto, California 94303
?
mi
from
Palo Alto, CA
Click here to add this to my saved trials